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Abstract
Hypoactive sexual desire disorder (HSDD) is the most prevalent female sexual dysfunction 
(FSD) and its bio-psychosocial multifactorial etiology justifies its multifaceted treatment. In 
Persian Medicine (PM), the weakness of the main organs (heart, brain and liver) is one of the 
important causes of lack of sexual desire; hence, their strengthening is a priority during treatment. 
Melissa officinalis is one of the medicinal plants with tonic characteristics for the main organs 
in PM and was used for treatment in this study. The aim of the present study was to evaluate 
the efficacy and safety of M. officinalis in the improvement of HSDD in women. Eighty nine 
(89) eligible women suffering from decreased sexual desire were randomly assigned to groups. 
The participants received medication (500 mg of aqueous extract of M. officinalis) or placebo 2 
times a day for 4 weeks. Changes in scores of desire, arousal, lubrication, orgasm, satisfaction 
and pain were evaluated at the end of 4 weeks of treatment using the Female Sexual Function 
Index (FSFI) questionnaire in the two groups. Forty three participants completed the study. The 
increase in desire (P < 0.001), arousal (P < 0.001), lubrication (P < 0.005), orgasm (P < 0.001), 
satisfaction (P < 0.001), pain (P < 0.002) and FSFI total score (P < 0.001) in the M. officinalis 
group was significantly more than that of the placebo group. The willingness to continue 
treatment was significantly higher in the M. officinalis as compared to the placebo group (P 
< 0.001). M. officinalis may be a safe and effective herbal medicine for the improvement of 
HSDD in women.
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Introduction
Female sexual dysfunction (FSD) is a very 
prevalent health problem which affects 25 to 65% 
of women (1). The prevalence of FSD has been 
estimated to be 43% in America (2) and reported 
to be 31.5% in Iran (1). Hypoactive sexual 
desire disorder (HSDD) is the most prevalent 
sexual dysfunction in women of all ages (3) 
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which impairs emotional health, interpersonal 
communication (4) and quality of life of women 
(3, 5).
HSDD in the Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition, Revised 
(DSM-IV-TR) is defined as persistent or recurrent 
deficiency (or absence) of sexual fantasies and 
desire for sexual activity which causes marked 
distress or interpersonal difficulties that cannot be 
explained by any other mental disorder (except 
another sexual dysfunction) or the direct effect 
of a substance, and there is no better definition 
for it in general medical disorders (6). Female 
hypoactive sexual desire disorder and female 
arousal disorder have been merged into one 
disorder: female sexual interest/arousal disorder 
in the DSM 5th Edition (DSM-5) (7).
Complex and multifaceted etiology of HSDD 
includes physiological, psychological and 
sociological factors which justifies its multifaceted 
intervention (3, 4). Psychotherapy, behavioral 
and sex therapy in addition to Pharmacotherapy 
are considered as the recognized interventions 
in the domain of decreased sexual desire (5). 
Transdermal testosterone (3), Bupropion (8), 
Bremelanotide (9), Dehydroepiandrosterone 
(10) and Flibanserin (5) are some of the drugs 
used for decreased sexual desire in women, 
and among these, only Flibanserin (5) has been 
recently accepted by America Food and Drug 
Administration (FDA) (11).
Medicinal plants for traditional medicine are 
focused on by researchers in different domains of 
medical science. Many clinical trials have been 
conducted in this regard to evaluate the effects 
of these drugs on different domains of FSD; 
these include study on Ginseng (12), Saffron 
(13), Elaeagnus angustifolia (14) and Tribulus 
terrestris (15).  According to Persian Medicine 
experts (such as Ibn Sina), strong and healthy 
body is essential for healthy sexual function 
which is essential for maintaining good health 
(16).
The valuable book, Canon of Medicine, was 
written by Ibn Sina (One of the most prominent 
Iranian scientists between 9 and 14 AD) (17). 
Chapter 12 of the third volume of this book is 
related to sexual health, measures and treatment of 
its disorders. In this chapter, libido is described as 
“Bah” (15) which explains the cause of decreased 
sexual desire, signs and treatment of any of the 
causes in detail (18). 
In Persian Medicine sources, weakness of the 
main organs (heart, brain and live) is one of the 
leading causes of decreased sexual desire (Bah). 
Accordingly, strengthening the main organs is 
the main priority of weak sexual desire treatment 
(18, 19). Melissa officinalis is one of the tonic 
drugs for the main organs in ITM (20). This 
medicinal herb was mentioned in PM with the 
name “Badranjboye”. The history of use of this 
medicinal plant is ancient Persia and its cultivation 
ability in different regions of Iran indicates that it 
is indigenous, available and it has been used for 
thousands of years in Iran (21).
M. officinalis or lemon balm (Labiate) is an 
aromatic and slightly spicy plant with lemon 
aroma and taste. The main components of the 
essential oil of M. officinalis are: geranial (citral 
a), neral (citral b) and citronellal. Phenolic acids 
(like rosmarinic acid) are the main components of 
M. officinalis aqueous extract which are mainly 
water-soluble (22, 23).
Recent animal and human studies have 
shown the different therapeutic applications of 
M. officinalis which are: as anti-anxiety (24), 
antidepressants (25, 26), for improvement of 
cognitive function and mood (27), for calming 
and positive effect on the immune system and 
stress (28), for Alzheimerꞌs disease (29), nervous 
sleeping disorders and functional gastrointestinal 
complaints (22). Even though the treatment of 
nervous debility has been reported to be among 
the pharmacological effects of M. officinalis in 
PDR which is used in folk medicine (23), there 
has not been any trial that evaluated its effect on 
the improvement of decreased sexual desire in 
women. 
The objective of this study was to evaluate the 
effect of M. officinalis extract on the improvement 
of sexual dysfunction in women aged 18 to 50 
years. 
Materials and methods
Study design
This was a randomized, double-blind, 
placebo-controlled study. The Ethics Committee 
of Shahed University approved the protocol 
(approval number: 41/195148). In addition, 
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it was registered in the Iranian Registry of 
Clinical Trials (Registration number: IRCT 
2014021516280N1).
The study was conducted in three centers: 
Shahid Mostafa Khomeini Hospital, Imam 
Khomeini Hospital and Salamatgah of Iranian 
Traditional Medicine- Shahed University, from 
July 2014 to October 2015.
Study population
The participants that qualified for the 
study were selected among 18 to 50 years old 
women referred to the mentioned centers with 
complain of decreased sexual desire. They were 
interviewed face-to-face in order to ensure the 
occurrence of decreased sexual desire in them. 
The whole process of interview, examination and 
history taking was done by traditional medicine 
assistant that was trained under the supervision 
of a gynecologist and psychiatrist. The interview 
was formed based on DSM-IV-TR criteria for 
HSDD (6).
The participants entered into the study after 
history taking, examination and completing 
the FSFI questionnaire (30) and if they met the 
inclusion criteria.
Inclusion criteria: this included women 
aged 18 to 50 years with satisfying emotional 
relationship with husband and sexually active at 
least for one year and having sexual intercourse 
at least once a month, decreased sexual desire 
(with a score equal to or less than the cut-off 
point of sexual desire domain (3.3) in the FSFI 
questionnaire), lack of pregnancy and lactation, 
lack of retard menstrual for 2 months or more 
and normal pelvic exam.
Exclusion criteria:   this included losing 
emotionally satisfying relationship with 
husband, the addition of another sexual partner 
during the study, the presence of any organic, 
anatomical or hormonal disease in the study 
group, such as: diabetes, cerebrovascular 
disease, damaged liver and kidney function, heart 
disease, hypothyroidism, history of cancers  and 
psychiatric disorders under medication therapy, 
smoking, using alcohol, drug abuse and taking 
any chemical or herbal drug which has effect on 
sexual desire. 
Details about the project and its purpose 
were provided by the researcher. Thereafter, the 
participants completed the consent form before 
enrolment into the study. 
Participants in both groups had the right to 
withdraw from the project at any time.
Medicine Preparation
Dried leaves of M. officinalis were purchased 
from the Firuze botanical Garden at Shahriar, 
Tehran, Iran.
The plant was authenticated and deposited at 
Shahid Beheshti University of Medical Sciences 
(SBUM) herbarium with voucher no. 8022- 
sbum.
Preparation of the plant extract was done at 
Traditional Medicine Department, Faculty of 
Medicine, Shahed University.  
An aqueous extract of the dried leaves of M. 
officinalis in boiling water was prepared. The 
extract was concentrated and then filled in 500 
mg capsules. The placebo was prepared from 
starch.
The medication was provided in identical 
500 mg capsules, containing either M. officinalis 
extract or placebo. The participants received 
either M. officinalis extract or placebo, 2 times a 
day, each time 2 capsules an hour after breakfast 
and dinner.
Medicine standardization
Total phenolic compounds of M. officinalis 
aqueous extract were determined with Folin–
Ciocalteu’s reagent (31) using gallic acid as a 
standard phenolic compound. The total phenolic 
content in the extract was 3.32±0.02 mg GA/g. 
The content of flavonoids in the extract was 
measured with spectrophotometric method (32) 
using rutin as a standard. The total flavonoids 
content in the examined extract was 1.8±0.003 
mg RU/g.
Interventions
The participants were randomly divided 
into two groups: the M. officinalis and placebo 
groups. Randomization was performed using 
block randomization and blocks of four at a ratio 
of 1:1 which were assigned to both groups were 
used.
Participants received M. officinalis extract 
or placebo according to the code provided by 
Traditional Pharmaceutical Group of Shahed 
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University and those based on the same guidelines 
were used.
Participants and researcher were unaware of 
the medications included in the box (a double-
blind randomized clinical trial).
Pharmaceutical capsules were packed in 2 
containers. The first container was given to the 
participants at this stage and the second one was 
given to them after 2 weeks. The shape of capsules 
and containers was the same in both groups.
Physical and gynecological examinations 
together with demographic and base data 
and medical history collection were done at 
the beginning of the study.  Also, frequency 
of intercourse in a month was asked and the 
participants were asked to fill FSFI questionnaire.
Follow-up on the correct use of the medicine by 
participants was done by researcher using phone 
calls after 48 to 72 h. Participants completed the 
side effects form at the end of the second week 
at the time of receiving the second package of 
the medicine. FSFI questionnaire and side effects 
questionnaire were filled at the end of the fourth 
week. Changes in the frequency of intercourse in 
a month were also recorded.
The participants were asked the following 
questions in order to evaluate the effectiveness of 
the treatment: Has the distress caused by sexual 
dysfunction been improved? and the global 
efficacy question (GEQ: “Did the treatment 
you received improve meaningful your sexual 
desire?”), and overall participant satisfaction 
question (“Are you satisfied with the efficacy of 
your treatment?”).
They were also asked to state their willingness 
to continue the treatment after the end of the study 
(8). The questionnaire for participants who used 
at least 80% of drugs was used for extraction of 
results.
Outcomes
Participants answered FSFI questionnaire 
based on their sexual function during the 4 weeks 
(at the beginning of the study and the end of 
the fourth week). Self-reported Female Sexual 
Function Index (FSFI) questionnaire had 19 
questions which evaluated the sexual function of 
women in 6 domains (desire, arousal, lubrication, 
orgasm, satisfaction and pain).
Each domain has different coefficient and 
questions. Questions of each domain are different: 
sexual desire (questions 1 and 2), arousal (3-6), 
lubrication (7-10), orgasm (11-13), satisfaction 
(14-16) and pain (17-19).Scores of each domain 
were obtained from the sum of scores of the 
questions in each domain multiplied by the 
coefficient of that domain. Higher scores indicate 
the better sexual function in each domain. The 
questions have five answers and the range of 
scores is from 1 to 5. The coefficient of desire is 
0.6. The score of this domain is variable, between 
1.2 and 6. 
The Cut-off point was defined for each domain 
and lower point of the cut-off point indicates poor 
function in that domain. Sexual desire which is 
the primary outcome of the study and secondary 
outcomes such as arousal, lubrication, orgasm, 
satisfaction and pain questionnaire’s total score 
were compared in both groups by FSFI.
Comparison of the frequency of intercourse 
in a month was done between the two groups 
before and after treatment. The evaluation of 
the improvement of distress caused by sexual 
dysfunction was done at the end of the fourth 
week by obtaining a yes or no answer from the 
participants. The answer to the GEQ which is: did 
the treatment you received improve meaningful, 
your sexual desire? and overall participant 
satisfaction question which is: are you satisfied 
with the efficacy of your treatment? had five 
options including very high, high moderate, low, 
very low or none. Finally, the participants were 
asked to express their willingness to continue the 
treatment after the end of the study by answering 
yes or no. The side effects were recorded in the 
second and fourth weeks using the side effects’ 
check list.
Sample size & statistical analysis  
The formula for comparing two means was 
used to calculate the sample size which was 38 
individuals (19 for each group) by considering the 
type I error of 0.05, study power of 80% and 12.5 
standard deviation observed in the pilot study and 
for at least 10 points difference in the drug group 
as compared to the placebo (one-way).
Description of quantitative data was 
done using mean and standard deviation and 
description of qualitative data was done using 
frequency percentage.
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P value lower than 0.05 was considered to be 
statistically significant.
Comparison of quantitative variables between 
the groups was carried out using student t-test and 
Mann-Whitney U test. Chi square test was used 
to compare the qualitative variables between the 
two groups.
Results
Participants
Initially, 149 participants complaining of 
decreased sexual desire were interviewed and 
89 of them that were eligible were randomly 
selected: 45 and 44 in the M. officinalis and 
placebo groups, respectively (Figure 1).
Sixty of them were excluded before 
randomization among which, 34 did not meet 
the inclusion criteria, 16 met the exclusion 
criteria and 10 refused to sign a consent. From 
the 58 participants that received treatment 
(30 participants that received M. officinalis extract 
and 28 that received placebo), 7 discontinued 
the intervention (2 in M. officinalis group and 
5 in placebo group) and 8 missed the follow-up 
(6 in M. officinalis group and 2 in placebo group). 
Among the 7 participants who discontinued the 
intervention, 2 were afraid of using M. officinalis, 
2 were afraid of receiving Placebo, 1 had family 
disputes and 2 had personal reasons.
The basic characteristics of the study 
participants are presented in Table 1. There 
was no significant difference between basic 
characteristics of these two groups. Mean 
(± SD) age was 35.5 (7.2) and body mass index 
(BMI) was 24.8 (3.4).There was no significant 
difference in the two groups at the beginning 
of the study (P = 0.960) with regards to sexual 
intercourse in a month. Forty three participants 
(22 in M. officinalis group and 21 in the placebo 
group) completed the study.
Analysis of the outcomes
Desire, the first outcome of the study, was 
evaluated by the FSFI questionnaire at the 
baseline and 4 weeks after starting the treatment. 
The base scores of desire did not show significant 
difference between the two groups (P = 0.361) 
(Table 2). The results showed a significant 
increase in the scores of desire in the M. officinalis 
group as compared to the Placebo group after the 
end of the 4th week of the treatment (P = 0.001) 
(Figure 2).
Arousal was another variable of the study, 
evaluation of its scores by the FSFI questionnaire 
indicated that its base scores did not show 
significant difference between the two groups 
(P = 0.439) while a significant difference was 
observed in arousal between the M. officinalis 
and Placebo groups after the intervention 
(P = 0.001) (Table 2).
The base scores of lubrication did not show 
significant difference between the two groups 
(P = 0.542). The mean (SD) of this domain 
increased from 3.21 (1.3) and 3.44 (1.3) at 
the baseline to 4.93 (0.75) and 3.90 (1.2), 
Table 1. Baseline characteristics of study subjects.
characteristic Melissa officinalis group (n = 22) Placebo group (n = 21) P value
Age (years), mean ± SD
Patient 35.2 (7.9) 35.4(6.7) .893
Partner 42.5(9.7) 41.6(6.5) .817
Body mass index (Kg/m2), mean ± SD 24.4 (2.9) 25.2(3.9) .913
Duration of marriage (years),  mean ± SD 2.9(8.8) 3.9(7.9) .855
Occupational status:
Housewife, n (%) 15(51.7%) 14(48.3%) .916
Employed, n (%) 7(50.0%) 7(50.0%)
Frequency of sexual activity (Baseline), mean ± SD 4.4 (2.75) 4.1 (.42) .960
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Table 2. Changes in FSFI domains scores from baseline to the end of 4 weeks of treatment.
Domains 
(mean ± SD) groups Baseline P value After 4 weeks P value intragroup Changes P value
Desire
M. officinalis 1.99 (.65) 0.36 4.28(.62) 0.001 2.2(0.4)
<0.001
placebo 2.17 (.67) 2.80(.85 ) 0.6(0.4)
Arousal
M. officinalis 2.69 (.90) 0.43 4.51(.63) 0.001 1.8(0.9)
<0.001
placebo 2.88(.95) 3.27(.93) 0.3(0.8)
Lubrication
M. officinalis 3.21 (1.3) 0.54 4.93(.75) 0.005 1.7(0.4)
0.001
placebo 3.44(1.3) 3.90(1.2) 0.4(1.2)
Orgasm
M. officinalis 2.96 (1.2) 0.93 4.87(.80) 0.001 1.9(0.8)
<0.001
placebo 2.97(.96) 3.23(.94) 0.2(0.7)
Satisfaction
M. officinalis 3.30 (.86) 0.52 5.18(.77) 0.001 1.8(0.6)
<0.001
placebo 3.52(.93) 4.00(.80) 0.4(0.8)
Pain
M. officinalis 4.50 (1.1) 0.73 5.56).65( 0.002 1.06(1)
0.002
placebo 4.48(.99) 4.78).85 ( 0.2(0.5)
Total FSFI score
M. officinalis 18.5 (4.2) 0.51 27.9(6.0) 0.001 9.3(6.6)
<0.001
placebo 19.4 (3.9) 21.7(3.9) 2.2(4)
 P value for comparison between groups.
 
Figure 1. Flow diagram of recruited patients 
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respectively in the M. officinalis and placebo 
groups according to FSFI questionnaire which 
show a significant increase in the results of the 
M. officinalis group as compared to the placebo 
group (P = 0.005) (Table 2).
The base scores of orgasm did not show 
significant difference between the two groups 
(P = 0.932). The changes in orgasm from the 
baseline till the end of the treatment were 
significant between the M. officinalis and placebo 
groups (P = 0.001) (Table 2).
The scores of satisfaction were also evaluated 
by FSFI questionnaire at baseline and after the 
intervention. Similar to other domains, there 
was no significant difference between the two 
groups at the baseline (P = 0.542). Increased 
scores of the M. officinalis after intervention was 
significant as compared to the placebo group 
(P = 0.001) (Table 2).
Another variable evaluated by FSFI 
questionnaire was pain. The base scores of pain 
did not show significant difference between the 
M. officinalis and Placebo groups (P = 0.732). 
The results after completion of treatment 
showed significant improvement in pain in the 
M. officinalis group as compared to the placebo 
group (P = 0.002) (Table 2).
There was no significant difference between 
the two groups at the baseline (P = 0.519) with 
regards to the total score of FSFI.  The mean (SD) 
of this domain increased form 18.5 (4.2) and 19.4 
(3.9) at the baseline to 27.9 (0.6) and 21.7 (3.9), 
respectively in the M. officinalis and placebo 
groups according to the FSFI questionnaire 
which showed a significant increase in the 
results of the M. officinalis group as compared to 
the placebo group (P = 0.001) (Table 2).
The mean (SD) frequency of sexual 
intercourse in a month showed a significant 
increase of 9.0 (3.4) in the M. officinalis group 
as compared to 4.3 (2.3) in the placebo group, at 
the end of the study (P = 0.001).
The participants were asked the GEQ: 
“Did the treatment you received improve 
meaningful, your sexual desire?” The answer 
of the M. officinalis group showed a significant 
improvement after 4 weeks of treatment 
(P = 0.001) (Figure 3). The overall participant 
satisfaction question: “Are you satisfied with 
the efficacy of your treatment?” was also asked. 
The answer given by 7 participants (31.8%) in 
the M. officinalis group was “very high”, while 
none of the participants in the placebo group 
gave this answer. With regards to this question, 
11 (50%) participants in the M. officinalis group 
and 1 (4.8%) in the Placebo group gave a “high” 
answer. In general, the rate of overall satisfaction 
with treatment at the end of the study was 
significantly higher in the M. officinalis group 
as compared to the Placebo group (P = 0.001) 
(Figure 4). 
The participants were asked about their 
Figure 2. Sexual desire scores before and after the intervention.
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willingness to continue treatment. 20 (90.9%) 
in the M. officinalis group and 4 (19.0%) in the 
Placebo group responded positively and those in 
the M. officinalis group were significantly more 
willing to continue treatment as compared to 
those in the placebo group  (p = 0.001). 
Finally, 21 participants (95.5%) in the M. 
officinalis group and 6 (28.6%) in the Placebo 
group answered yes to the question: “Has the 
distress caused by sexual dysfunction been 
improved after 4 weeks of treatment?” There 
was a significant differences between the M. 
officinalis and placebo groups (P = 0.001) 
with regards to distress improvement, after the 
intervention.
Side effects
No serious side effect was reported in both 
groups during the study. Five side effects 
including nausea, diarrhea, constipation, 
increased vaginal discharge and vaginal bleeding 
were observed during the study period and in 
total, 2 participants (9.1%) in the M. officinalis 
group and 5 (23.8%) in the placebo group had 
side effects. The Side effects observed with 
M. officinalis extract were diarrhea (4.5%) and 
constipation (4.5%). The difference between 
the two groups in terms of side effects was not 
significant (P = .24).
Discussion
FSD is a very prevalent health problem and 
HSDD is the most prevalent sexual dysfunction 
in women of all ages which impairs emotional 
health, interpersonal communication (4) and 
quality of life of women (3, 5).
The present study showed improvement 
of the hypoactive sexual desire disorder by 
M. officinalis extract and the other domains of 
sexual dysfunction: arousal, lubrication, orgasm, 
satisfaction and pain, were improved using M. 
officinalis as well.
According to the opinions of Persian 
Medicine philosophers, the weakness of the 
main organs is an important cause of decreased 
sexual desire which makes their strengthening a 
priority during treatment (18, 19). M. officinalis 
boost multilaterally, the main organs in PM 
sources including Canon (33) and is useful in 
strengthening the heart, brain (18) and also the 
liver (20). M. officinalis was used in this study 
as a tonic for the main organs in the treatment of 
loss of sexual desire and it may have improved 
this disorder by strengthening the main organs; 
this finding confirm this hypothesis. The results 
of the present study support the unproven effects 
of M. officinalis on PDR for the improvement of 
nervous debility (23).
The demographic and baseline characteristics 
Figure 3. Summary of the participantsꞌ response to the GEQ; ‘Did the treatment you received during the 4 weeks improve meaningfully 
your sexual desire‘?
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of two groups of participants were similar. Thus, 
the improvement of sexual desire can be a result 
of M. officinalis extract due to its strengthening 
effects on the main organs in the participants.
According to the present survey, there is no 
other study on the effect of M. officinalis on 
sexual desire. The study evaluated the effect 
of M. officinalis extract on hypoactive sexual 
desire disorder using a double-blind randomized 
clinical trial for the first time.
Kennedy et al. (2006) and EmamGhoreishi 
and Talebianpoor (2009), respectively reported 
the anti-anxiety and antidepressant effects of M. 
officinalis (24, 25); the M. officinalis significantly 
improved the desire, arousal, orgasm and 
satisfaction of FSFI which can be due to its anti-
depressant and anti-anxiety effects. It seems 
that this point can be in line with opinions on 
ITM about strengthening the brain and heart 
by this plant which has also been mentioned 
in the Canon book (18, 20). Evaluation of the 
mechanism of M. officinalis in the study of 
EmamGhoreishi showed that M. officinalis 
aqueous extract probably had antidepressant 
effects by increasing norepinephrine (NE) 
similar to imipramine (22). Since NE plays a 
catalytic role in sexual desire (34, 35), the effect 
of M. officinalis on this domain may be related to 
this mechanism of action.
The effect of M. officinalis on improvement 
of cognitive performance and mood was reported 
by Kennedy et al. (27). Akhondzadeh et al. 
also used M. officinalis extract in the treatment 
of patients with mild to moderate Alzheimerꞌs 
disease. The studies showed that the mechanism 
of action of M. officinalis on the mentioned 
domain may be based on cholinergic activity 
and stimulation of CNS acetylcholine. The 
evaluation of the mechanism of M. officinalis 
aqueous extract on isolated rat heart in the study 
of Gazola et al. showed that the muscarinic 
receptor stimulation may lead to reduced heart 
rate without changes in contractions power (36). 
M. officinalis significantly increased the score of 
sexual arousal in the present study. According to 
studies, the parasympathetic nerve stimulation 
and release of acetylcholine are affective 
in the creation of the physical changes that 
occur during sexual arousal (including genital 
vascular vasodilatation) (33, 35). Even though 
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the mechanisms of action of M. officinalis on 
arousal of women is unknown and requires 
further researches, these genital changes caused 
by sexual arousal may be caused by the effect of 
M. officinalis on muscarinic receptors.
Ballard et al. showed the effect of M. 
officinalis on the treatment of agitation in severe 
dementia (37). Antimicrobial and antioxidant 
activities of M. officinalis were reported in 2004. 
The results of the current study are not in line 
with the findings of the studies mentioned.
Dopamine has a stimulatory effect on desire 
and subjective arousal and facilitates sexual 
behavior while prolactin plays an inhibitory role 
in this domain (34, 35, and 39). The study of 
Sourgens et al. showed that M. officinalis reduces 
the pituitary reserves and serum prolactin level 
which may be related to increased dopamine 
in the hypothalamus (26). The improvement of 
sexual desire observed in the current study can 
partly be related to the effect of M. officinalis 
on the above neurotransmitter-hormone system. 
However, more detailed studies are necessary to 
evaluate this mechanism.
The analgesic effect of M. officinalis has been 
reported in several studies (40, 41). It was shown 
in the study of Gorji et al. that the analgesic 
effect of M. officinalis aqueous extract may be 
due to its effect on opioid receptors; it was also 
observed that Naloxone reduces the analgesic 
effect of extract (40). The beneficial effect of M. 
officinalis on opioid withdrawal syndrome was 
reported in a review study of the effect of Iranian 
herbal medicines on opioid withdrawal syndrome 
(42). It was observed in the study of Wilson et 
al. in 2009 that opioids and neuropeptides can 
be effective on sexual pain disorder (43). Since 
the M. officinalis significantly improved pain 
domain score in this study, this effect may be due 
to action on opioid system.
No serious complication was observed in 
the present study and there was no significant 
difference between intervention and placebo 
groups in terms of side effects which indicates 
the safety of M. officinalis in the present study. M. 
officinalis is in the list of safe drugs in FDA (26) 
which is confirmed by the results of this study. 
This result is in line with safety information 
of M. officinalis in PDR and Commission E 
(22, 23) and supports safety findings of M. 
officinalis in other studies (27, 29, 33 and 37). 
Most drugs used to treat loss of sexual desire 
have side effects which prevents their effective 
use in treatment, among which are the potential 
side effects of androgens replacement therapy 
including acne, hirsutism, male-building, changes 
of the voice, erythrocytosis, hepatotoxicity, 
plasma lipid changes, etc. (44). Side effects such 
as acne and hirsutism which occur during the 
systemic administration of DHEA can be listed 
as examples (38). So, it seems that M. officinalis 
aqueous extract can be an effective and safe 
treatment for hypoactive sexual desire disorder. 
It is shown that M. officinalis is effective in 
the treatment of sexual dysfunction in women 
but privacy of sexual problems together with 
prudency arising from religion and culture are 
obstacles for participants to talk about sexual 
problems and may be the reason for difficult 
surveillance and the main reason for participants 
leaving the study. It is suggested that M. officinalis 
should be used in larger samples, different 
statistical populations and longer studies. 
Conclusions
M. officinalis aqueous extract improved 
desire in women with hypoactive sexual desire 
disorder and had beneficial effects on sexual 
arousal, lubrication, orgasm, satisfaction and 
pain domains of the sexual dysfunction in women 
and may be used as an effective and safe therapy 
in female sexual dysfunction.
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